Entrada Therapeutics (TRDA) Interest Expenses (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Interest Expenses of $18000.0 for Q1 2026, down 86.57% year-over-year from $134000.0 in Q1 2025, and little changed quarter-over-quarter from $18000.0 in Q3 2025.
Entrada Therapeutics (TRDA) Interest Expenses (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Interest Expenses fell 86.57% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $18000.0 (down 86.57% YoY), while the FY2025 annual figure was $12.7 million, down 79.89% from the prior year.
- Interest Expenses for Q1 2026 stood at $18000.0, roughly flat from $18000.0 in the prior quarter.
- The five-year high for Interest Expenses was $102.4 million in Q2 2023, with the low at -$13.2 million in Q4 2023.
- The 5-year median for Interest Expenses is $317500.0 (2024), against an average of $16.1 million.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses tumbled 134.82% in 2023, then jumped 578.11% in 2024.
- Entrada Therapeutics' Interest Expenses stood at -$5.6 million in 2022, then sank by 134.82% to -$13.2 million in 2023, then surged by 578.11% to $62.9 million in 2024, then sank by 99.97% to $18000.0 in 2025, then changed by 0.0% to $18000.0 in 2026.
- Business Quant data shows TRDA's Interest Expenses at $18000.0 in Q1 2026, $18000.0 in Q3 2025, and $114000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23,000.00 |
| Jun 30, 2026 | 23,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Mar 31, 2025 | 134,000.00 |
| Mar 31, 2025 | 134,000.00 |
| Dec 31, 2024 | 62.94 Mn |
| Dec 31, 2024 | 62.94 Mn |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 353,000.00 |
| Jun 30, 2024 | 353,000.00 |
| Mar 31, 2024 | 282,000.00 |
| Mar 31, 2024 | 282,000.00 |
| Dec 31, 2023 | -13.16 Mn |
| Dec 31, 2023 | -13.16 Mn |